SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

RAGE GUY (RAGE) is a cryptocurrency inspired by the Rage Guy meme, one of the earliest and most recognizable characters from internet rage comics. The project captures the cultural legacy of early meme history and brings it onto the blockchain in tokenized form. It is designed as a community-driven digital asset that celebrates internet culture, nostalgia, and the role memes play in shaping online communities.

Rage Guy

Rage Crypto is trending as its community leans into the project's roots as an internet culture OG, actively promoting their restored original comic-making tools to generate viral, cross-platform engagement. Supporters are focused on aggressive grassroots 'bagworking' and building a dedicated following, framing the project as a highly undervalued play on historical meme nostalgia.

"What's Updog?" is a Community Led token.

UpDog

UpDog is trending as the community highlights its multi-year track record and organic growth on the Solana network while actively encouraging others to load their bags. Participants are rallying behind the ticker with memes and dad jokes, emphasizing the project's presence on the Jupiter strict list as a core point of interest.

OpenGradient is the Network for Open Intelligence — a decentralized infrastructure network designed to host, inference, and verify AI models at scale. Rather than functioning as a standalone blockchain, OpenGradient operates as a specialized AI coprocessor: it enables applications, blockchains, and autonomous agents to outsource computationally-heavy AI tasks to a dedicated network of GPU and Trusted Execution Environment (TEE) nodes. The validator set verifies every computational proof (TEE attestation or zkML proof) at the consensus level before it is committed on-chain, enabling trustless usage of AI from any network or application.

OpenGradient

OpenGradient is gaining momentum as a newly listed token benefiting from increased trading volume and heightened public awareness. Investors are actively discussing the asset's growth potential while comparing it to other high-volatility projects following recent exchange launches.

Aerodrome Finance is a next-generation AMM designed to serve as Base's central liquidity hub, combining a powerful liquidity incentive engine, vote-lock governance model, and friendly user experience. Aerodrome inherits the latest features from Velodrome V2.

Aerodrome Finance

Aerodrome Finance is attracting significant community attention as investors debate its role as a key liquidity hub on the Base ecosystem, with many closely tracking its ongoing revenue generation and supply-reduction efforts. While some discuss the potential for long-term growth driven by institutional interest and upcoming network expansions, others are navigating recent price volatility and debating the merits of accumulation at current levels.

ETHGas is a Blockspace Infrastructure protocol that decomposes Ethereum blockspace into tradable, composable block units, enabling real‑time block production and laying the foundation for a crypto‑native commodities market for gas. By restructuring gas as a financial primitive, ETHGas unlocks: - Faster block times (sub‑second confirmations vs 12‑second Ethereum blocks) through real‑time sequencing. - A futures/forward market for gas, enabling the creation of a native Ethereum yield curve. - Gas abstraction for end users via the Open Gas Initiative, removing gas volatility and shifting costs to protocols. - Commoditization of blockspace, similar to energy or metals markets in traditional finance.

ETHGas

GWEI is gaining attention as a momentum-driven Ethereum ecosystem token following new listings on major exchanges and growing optimism surrounding upcoming legislative clarity in the crypto sector. Community members are actively discussing its price resilience and staking utility while monitoring broader market catalysts for a potential bull cycle.

The TROLL token on the Solana network is a meme coin inspired by internet trolling culture, designed for entertainment and community engagement with no intrinsic value. Built on Solana’s blockchain, it leverages the network’s fast transactions and low fees to appeal to meme enthusiasts. Launched on decentralized exchanges, TROLL aims to foster a fun, community-driven ecosystem through social media, influencer partnerships, and viral marketing, embodying the playful spirit of online trolling.

Troll

The $TROLL community is heavily promoting the coin as a classic memetic powerhouse, drawing comparisons to other high-profile internet culture tokens. Investors are actively discussing the project's roots in viral Rage Comics while pushing for broader market adoption through community-driven content and social media awareness.

Dumb SEND IT

Dumb SEND IT ($DSIT) is gaining traction as investors flock to the newly launched, low-cap meme coin, with the community actively rallying to drive growth through social media engagement and trending efforts. Supporters are focused on the developer's commitment to transparency and periodic airdrops as they work to overcome early liquidity hurdles and build momentum on Solana-based platforms.

The Aircoin memecoin was born from a viral Twitter post from March, 2014 which proclaimed the following:   Evolution: 1. Aircoin 2. Fartcoin 3. Artcoin  Aircoin was launched in August, 2025 and CTO'd twice, with the second CTO team bringing vast experience and expertise to the project. The team includes industry veterans and visual arts professionals.  Aircoin is destined for greatness as a premier memecoin on the BONK.fun platform.

aircoin

$AIRCOIN is gaining attention on Solana due to its long-term community conviction, characterized by high token lock rates and significant holder retention. Investors are highlighting the project's consistent development and treasury growth as a differentiator from typical short-lived memecoin trends.

Orca is the most user-friendly DEX on Solana.  Orca is one of the first general-purpose AMMs launched on Solana. Users can swap assets, provide liquidity, and earn yield through an easy-to-use interface. Projects can use Orca as a money-lego to easily integrate swapping, farming, or on-chain data into their dApp.  Orca strives to provide easy and effective financial tools for everyone, bringing DeFi to the masses.

Orca

Orca is seeing massive buying momentum and volatility as traders discuss a potential short squeeze fueled by high short interest and market anticipation of upcoming DAO-led buyback programs. The community is actively debating the token's low circulating supply as a catalyst for potential upside while keeping a close watch on key technical levels.

PENGU is the official coin of Pudgy Penguins.  Pudgy Penguins has become the face of crypto with one of the most influential communities in the industry. From large companies wearing the Penguin, to being featured in ETF commercials, to garnering millions of followers and over 100 billion views, the Pengu has become a cultural icon making PENGU the world’s social currency.  PENGU allows for the ever-expanding Pudgy Penguin fanbase and the hundreds of millions of people outside of crypto that see and share the Pudgy Penguin everyday, to join The Huddle. PENGU is a symbol for community, memes, and good vibes.  Believe in Pengu. Believe in the Prophecy.

Pudgy Penguins

Pudgy Penguins is trending as holders discuss its transition from a niche digital asset to a phygital powerhouse, fueled by its growing retail presence in major physical stores and utility-focused developments. The community remains focused on long-term accumulation, debating the potential for future price breakthroughs while drawing comparisons to established meme coins.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Global Equity ETFs in Focus as AI Optimism Drives Fresh Inflows

AI optimism and easing volatility fuel a $48.7B surge into global equity funds. Here are some global ETFs to consider.

Looking Abroad Again? Global ETFs to Diversify Beyond U.S. Markets

Ceasefire hopes, persistent volatility in the U.S. markets and a softer dollar are driving investors to look beyond domestic equities and toward global equity ETFs for broader diversification.

<ul class="summary-bullets"><li>FDA approved leucovorin in the treatment of cerebral folate transport deficiency last month but not in autism.</li><li>Leucovorin garnered attention in the latter half of 2025 after Donald Trump and his administration promoted it as an "exciting" and “promising” therapeutic for autism.</li><li>According to research published in The Lancet, outpatient leucovorin prescriptions for children aged 5–17 years increased by 71% following the press briefing in September.</li></ul>UK drugmaker GSK Plc (GSK) has withdrawn its application for the drug leucovorin calcium touted by President Trump as a potential treatment for autism.GSK asked the U.S. Food and Drug Administration to pull its application for leucovorin calcium because it no longer markets the medicine, a filing on the FDA website shows.The news was first reported by The Wall Street Journal. &nbsp;<h2 class="st-heading-2">Leucovorin Approval And Claims</h2>According <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.wsj.com/health/pharma/gsk-nixes-application-for-drug-touted-by-trump-for-autism-4d5bdead">to </a>WSJ, GSK said in September that it would submit an application for the drug in the treatment of cerebral folate transport deficiency following a request from the FDA. The agency approved the drug for the condition last month, but not for autism. The company, however, hasn’t sold the drug since 1999, the report noted. &nbsp;A GSK spokesperson reportedly told the newspaper that the company never intended to sell the drug again. Meanwhile, a spokesperson for the U.S. Department of Health and Human Services told the paper that GSK’s decision has no bearing on generic versions of the drug for patients with cerebral folate deficiency.Leucovorin garnered attention in the latter half of 2025 after Donald Trump and his administration promoted it as an "exciting" and “promising” therapeutic for autism. According to <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(26)00243-6/fulltext">research</a> published in The Lancet, outpatient leucovorin prescriptions for children aged 5–17 years increased by 71% following the press briefing in September where Trump made his claims with Robert F Kennedy Jr.<h2 class="st-heading-2">How Did Retail Traders React?</h2>On Stocktwits, retail sentiment around GSK stock stayed within the ‘bearish’ territory, while message volume remained at ‘low’ levels.<a href="https://stocktwits.com/symbol/GSK">GSK stock</a> has gained 69% over the past 12 months.&nbsp;Read More: <a href="https://stocktwits.com/news-articles/markets/equity/tsla-stock-heads-for-8th-straight-week-of-price-decline/cZJWlLZRIsZ">TSLA Stock Heads For 8th Straight Week Of Price Decline — What’s Driving The Selloff?</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the logo of GSK plc is displayed on a smartphone screen, on April 26, 2025, in Chongqing, China. (Photo illustration by Cheng Xin/Getty Images)

GSK Reportedly Pulls Application For Drug Touted By Trump As Potential Treatment For Autism

According to a report from the Wall Street Journal on Thursday, GSK asked the FDA to pull its application for leucovorin calcium because it no longer markets the medicine.

Equity

<ul class="summary-bullets"><li>Novo got approval for the higher dose of its Wegovy injection in March based on results from a late-stage clinical trial in which 89% of participants taking the higher dose achieved 5% or greater weight loss at 72 weeks.</li><li>Novo said on Tuesday that self paying adults prescribed Wegovy HD can expect a price of $399/month.</li><li>In January, Novo also launched its weightloss pill, in a bid to regain market share being eroded by rival Eli Lilly and Co.</li></ul>Shares of Novo Nordisk (NVO) saw increased retail chatter on Tuesday after the company announced the availability of its higher dose Wegovy injection across the U.S.On Stocktwits, retail sentiment around NVO stock stayed within the ‘neutral’ territory over the past 24 hours. Retail chatter around the stock jumped 136% over the same time frame.A Stocktwits user said that NVO stock remains “stubbornly undervalued.”<stembedurl>https://www.stocktwits.com/Johnnytwofour2/message/649581803</stembedurl>Another sounded hopes for a big move.<stembedurl>https://www.stocktwits.com/jonztown/message/649554573</stembedurl>The Wegovy HD injection 7.2 mg will be available through over 70,000 U.S. pharmacies, including Novo’s own NovoCare Pharmacy and select telehealth providers, the company <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.prnewswire.com/news-releases/novo-nordisks-wegovy-hd-available-now-nationwide-302735677.html">said</a>. The higher dose delivers the highest weight loss of any Wegovy injection to date. &nbsp;<h2 class="st-heading-2">Wegovy HD Approval</h2>Novo got approval for the higher dose of its Wegovy injection in March based on results from a late-stage clinical trial in which 89% of participants taking the higher dose achieved 5% or greater weight loss at 72 weeks as compared to 38% amongst those taking placebo.Prior to its approval, the highest approved dose of Wegovy injectable for weight loss was 2.4 mg.Novo said on Tuesday that self paying adults prescribed Wegovy HD can expect a price of $399/month.“Whether patients haven't yet reached their weight loss goals on lower-dose Wegovy injectables, or they simply have a more significant amount of weight to lose, the 21% weight loss demonstrated in the STEP UP trial, if all patients stayed on treatment, shows what's possible with this new dose, and that's an opportunity we're excited to provide," said Ed Cinca, senior vice president, Marketing and Patient Solutions at Novo Nordisk.<h2 class="st-heading-2">Novo Outlook</h2>In January, Novo also launched its weightloss pill, in a bid to regain market share being eroded by rival Eli Lilly and Co (LLY).However, the company now expects its adjusted sales growth for 2026 to be down 5% to 13% at constant exchange rates, owing to lower realised prices and competition, among other factors.<a href="https://stocktwits.com/symbol/NVO">NVO stock</a> is down 42% over the past 12 months.&nbsp;Read More: <a href="https://stocktwits.com/news-articles/markets/equity/hyperscale-data-reports-nearly-double-its-market-cap-in-assets/cZJJwKlRIpM">Hyperscale Data Reports $102 Million In Assets, Nearly Double Its Market Cap</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the logo of Novo Nordisk is displayed on a smartphone screen on September 10, 2025 in Chongqing, China. 

Novo Nordisk Launches Higher Dose Of Wegovy Injection Across US — Retail Thinks Stock Is ‘Terribly Undervalued’

The Wegovy HD injection 7.2 mg will be available through over 70,000 U.S. pharmacies including Novo’s own NovoCare Pharmacy and select telehealth providers, the company said.

<ul class="summary-bullets"><li>Analysts at BofA nearly doubled their price target for HIMS stock following the company’s deal with Novo.</li><li>The firm now has a price target of $23, up from $12.5, while the rating has been upgraded to ‘Neutral’ from ‘Underperform’.</li><li>The firm stated that Novo dropping its patent infringement lawsuit against Hims is a “clear positive” for the telehealth operator.</li></ul>Novo Nordisk AS’s (NVO) deal with Hims &amp; Hers Health Inc. (HIMS) has turned Wall Street bullish on both companies, with analysts stating that it helps them in dealing with a commercial headwind and removes a litigation risk from the equation.According to TheFly, analysts at BMO Capital noted that the&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/hims-stock-soars-novo-nordisk-drops-patent-suit-hims-hers-partnership-ozempic/cZdVZe7RIIk">Novo Nordisk-Hims deal</a> to sell branded GLP-1 is a significant step forward in helping the Ozempic maker address a commercial headwind.The firm maintained its ‘Market Perform’ rating for Novo Nordisk, with a price target of $45, implying an upside of more than 13% from NVO stock’s closing price on Monday.<a href="https://stocktwits.com/symbol/NVO">Novo shares</a> were down about 1% in Tuesday’s pre-market trade, while&nbsp;<a href="https://stocktwits.com/symbol/HIMS">Hims &amp; Hers shares</a> were up nearly 5% at the time of writing. Retail sentiment around HIMS stock trended in the ‘extremely bullish’ territory on the platform.<h2 class="st-heading-2">Why Are Analysts Bullish On HIMS?</h2>Analysts at BofA nearly doubled their price target for HIMS stock following the company’s deal with Novo. The firm now has a price target of $23, up from $12.5, while the rating has been upgraded to ‘Neutral’ from ‘Underperform’.The firm stated that Novo dropping its patent infringement lawsuit against Hims is a “clear positive” for the telehealth operator. BofA sees the risk-to-reward ratio as balanced now following the deal.Deutsche Bank also hiked its price target for HIMS to $28 from $25, implying an upside of more than 26% from Monday’s closing price. The firm cited the Novo deal for its price target hike, while keeping a ‘Hold’ rating on the HIMS stock.<h2 class="st-heading-2">What Did Novo, Hims Agree On?</h2>Hims and Novo Nordisk announced a partnership to offer Ozempic and Wegovy at affordable self-pay prices on the telehealth company’s platform.Hims &amp; Hers also stated that it will no longer advertise compounded GLP-1 offerings on its platform or in its marketing. The company stated that Ozempic injections in doses of 0.5 mg, 1 mg, and 2 mg are covered. It will also include Wegovy injections in 1.7 mg and 2.4 mg doses, while Wegovy pills in 1.5 mg, 4 mg, 9 mg, and 25 mg doses are covered.It added that these Ozempic and Wegovy offerings will be made available on its platform later this month.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>One bullish user on Stocktwits believes selling HIMS stock at this point will be one of the “biggest mistakes” of their life.&nbsp;<stembedurl>https://stocktwits.com/TradeOrGoHome/message/647084706</stembedurl>Another user stated that every dip in the NVO stock is a “gift.”<stembedurl>https://stocktwits.com/King_of_the_bagholders/message/647086431</stembedurl><a href="https://stocktwits.com/symbol/NVO">NVO stock</a> is down 22% year-to-date, while&nbsp;<a href="https://stocktwits.com/symbol/HIMS">HIMS stock</a> is down 32%.Also See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/iran-war-hegseth-most-intense-day-of-strikes-iranian-leaders-scrambling/cZdoAnzRI75">Iran War: Defense Secretary Hegseth Warns Of ‘Most Intense’ Strikes, Says The Middle East Country Is ‘Badly Losing’</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Novo Nordisk-Hims Deal Turns Wall Street Bullish — BMO Sees Relief From Commercial Headwinds, BofA Upgrades HIMS Stock

BMO Capital maintained its ‘Market Perform’ rating for Novo Nordisk, with a price target of $45, implying an upside of more than 13% from NVO stock’s closing price on Monday.

<ul class="summary-bullets"><li>Hims &amp; Hers said that existing patients will have the opportunity to transition to FDA-approved medicines when their providers deem it clinically appropriate.</li><li>The company stated that Ozempic injections in doses of 0.5 mg, 1 mg, and 2 mg are covered.</li><li>It will also include Wegovy injections in 1.7 mg and 2.4 mg doses, while Wegovy pills in 1.5 mg, 4 mg, 9 mg, and 25 mg doses are also covered.</li></ul>Shares of Hims &amp; Hers Health Inc. (HIMS) surged more than 52% in Monday’s pre-market trading after Novo Nordisk A/S (NVO) partnered with the telehealth platform to offer Ozempic as well as Wegovy at affordable self-pay prices and dropped its patent infringement lawsuit against the company.Hims &amp; Hers also stated that it will no longer advertise compounded GLP-1 offerings on its platform or in its marketing. Existing patients will have the opportunity to transition to FDA-approved medicines when determined clinically appropriate by their providers, the company said.<a href="https://stocktwits.com/symbol/NVO">Novo shares</a> were up more than 2% in Monday’s opening trade, while&nbsp;<a href="https://stocktwits.com/symbol/HIMS">Hims &amp; Hers shares</a> were up around 39% at the time of writing. Retail sentiment around HIMS stock trended in the ‘extremely bullish’ territory on the platform.<h2 class="st-heading-2">What Does The Agreement Include?</h2>Hims &amp; Hers stated that the Ozempic and Wegovy offerings will be made available on its platform later this month.This includes Ozempic injections in doses of 0.5 mg, 1 mg, and 2 mg and will also include Wegovy injections in doses of 1.7 mg and 2.4 mg. Wegovy pills in 1.5 mg, 4 mg, 9 mg, and 25 mg doses are also covered.Over the coming months, Hims &amp; Hers will educate U.S. weight loss customers about their options across a wider range of FDA-approved treatments. When providers determine it is clinically appropriate, the company will help support a smooth transition to these medications, the company said.<h2 class="st-heading-2">Novo’s Allegations</h2>In&nbsp;February this year, Novo had sued Hims &amp; Hers,&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/novo-nordisk-sues-hims-hers-permanent-ban-unapproved-compounded-drugs/cZbHzMjR4o2">stating</a> that the latter is duping consumers and healthcare professionals about the clinical benefits and safety of these unapproved drugs.The U.S. Food and Drug Administration (FDA) also warned of a crackdown last week on GLP-1 active pharmaceutical ingredients (APIs) intended for use in non-FDA-approved compounded drugs.“These actions are aimed to safeguard consumers from drugs for which the FDA cannot verify quality, safety, or efficacy.&nbsp; We take seriously any potential violations of the Federal Food, Drug, and Cosmetic Act,” the agency said.Subsequently, Hims &amp; Hers announced that it would stop offering the $49 compounded version of Novo’s Wegovy.<a href="https://stocktwits.com/symbol/NVO">NVO stock</a> is down 23% year-to-date, while&nbsp;<a href="https://stocktwits.com/symbol/HIMS">HIMS stock</a> is down 33%.Also See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/ibrx-stock-declines-immunitybio-resubmits-anktiva-application-to-fda/cZdVj9URIIL">ImmunityBio Resubmits Supplemental Biologics License Application To FDA For Ankitva — IBRX Stock Declines Pre-Market</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the Hims & Hers Health logo is seen displayed on a smartphone screen. (Photo Illustration by Thomas Fuller/SOPA Images/LightRocket via Getty Images)

HIMS Stock Soars After Novo Nordisk Drops Patent Infringement Lawsuit, Opens Access To Ozempic, Wegovy

Hims & Hers also stated that it will no longer advertise compounded GLP-1 offerings on its platform or in its marketing.

<ul class="summary-bullets"><li>Novo Nordisk stated that its price cuts for Ozempic and Wegovy are intended to benefit insured patients.</li><li>The company said this will also benefit patients who pay out of pocket, but their costs are tied to the list price of these drugs.</li><li>Novo Nordisk said this applies to patients with high-deductible health plans or co-insurance benefit designs.</li></ul>Novo Nordisk AS (NVO) is planning to cut Ozempic and Wegovy prices in the U.S. by up to 50% starting in 2027.Ozempic and Wegovy prices will start at a list price of $675 a month, effective Jan. 1, 2027, according to the company. This is a 50% reduction when compared to the current list price of Wegovy, and about 35% cut for the list price of Ozempic.“Lowering the list price of Wegovy and Ozempic is the best approach to address the unprecedented opportunity to help more than 100 million people living with obesity and over 35 million people with type 2 diabetes in the United States,” said Jamey Millar, Novo Nordisk’s Executive Vice President of U.S. operations.<a href="https://stocktwits.com/symbol/NVO">Novo Nordisk shares</a> were down nearly 2% in Tuesday’s opening trade. Retail sentiment on Stocktwits around the company trended in the ‘bullish’ territory with message volumes at ‘extremely high’ levels at the time of writing.<h2 class="st-heading-2">Who Will Benefit From These Lower Prices?</h2>Novo Nordisk stated that its price cuts for Ozempic and Wegovy are intended to benefit insured patients.This will also benefit patients who pay out of pocket, but whose costs are linked to the list price of these drugs. This applies to patients with high-deductible health plans or co-insurance benefit designs, the company said.Novo Nordisk added that Tuesday’s price cuts do not impact its direct-to-consumer and self-pay offerings of Ozempic and Wegovy.<h2 class="st-heading-2">Ozempic And Wegovy Prices For Cash-Paying Patients</h2>Novo Nordisk currently offers Wegovy for cash-paying patients, starting at $149 per month for the pill and $199 per month for the pen.Ozempic prices start at $199 a month for the first two months for new patients for 0.25 mg and 0.5 mg doses.Existing patients can get Ozempic in 0.25 mg, 0.5 mg, and 1 mg doses at $349 per month.All patients will have to pay $499 a month for the 2 mg dose of Ozempic.<a href="https://stocktwits.com/symbol/NVO">NVO stock</a> is down 24% year-to-date and 56% over the past 12 months.Also See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/amd-stock-soars-on-meta-expanded-6-gigawatt-deal-for-amd-gpus/cZRvDZZR4Cb">AMD Stock Soars Pre-Market After Meta Expands Multi-Year AI Chip Partnership</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Still life of Novo Nordisk's Wegovy semaglutide tablets with injectable prescription weight loss medicines, Ozempic, and Wegovy

Novo Nordisk To Cut Ozempic, Wegovy Prices By Up To 50%

Ozempic and Wegovy will start at a list price of $675 a month, effective Jan. 1, 2027, according to the company.

<ul class="summary-bullets"><li>The company stated that the UBT251 trial conducted by United Laboratories showed statistically significant improvements when compared to placebo on key secondary endpoints.</li><li>Novo Nordisk stated that from a baseline mean body weight of 92.2 kg, the highest mean weight loss observed for people treated with UBT251 was 19.7%, compared to 2% in the placebo group.</li><li>The company’s Chief Scientific Officer, Martin Holst Lange, added that Novo Nordisk is looking forward to reporting data from a global trial with UBT251 next year.</li></ul>Novo Nordisk AS (NVO) on Tuesday announced that its phase 2 clinical trial of a new obesity drug in China has shown successful results.Developed in partnership with United Laboratories International Holdings, Novo Nordisk said that UBT251 delivered up to 19.7% mean weight loss after 24 weeks in a phase 2 trial in China.However,&nbsp;<a href="https://stocktwits.com/symbol/NVO">Novo Nordisk shares</a> declined nearly 3% in Tuesday’s pre-market trade. Retail sentiment on Stocktwits around the company trended in the ‘bullish’ territory with message volumes at ‘extremely high’ levels at the time of writing.<h2 class="st-heading-2">UBT251 Trial Results Show Significant Improvements</h2>The company stated that the UBT251 trial conducted by United Laboratories showed statistically significant improvements compared with placebo on key secondary endpoints, including waist circumference, blood glucose, blood pressure, and lipids.The trial investigated the safety and efficacy of UBT251 at doses of 2 mg, 4 mg, and 6 mg.Novo Nordisk stated that from a baseline mean body weight of 92.2 kg, the highest mean weight loss observed for people treated with UBT251 was 19.7%, or about 17.5 kg, compared to 2% or 1.6kg in the placebo group after 24 weeks of treatment.“We are very encouraged by these data from the trial in China, which demonstrate the potential of UBT251 and its differentiated clinical profile and safety and tolerability profile,” said Novo Nordisk’s Chief Scientific Officer, Martin Holst Lange.Lange added that the company is looking forward to reporting data from a global trial with UBT251 next year.<h2 class="st-heading-2">Why Is NVO Stock Declining Pre-Market?</h2>Novo Nordisk shares continued to decline in Tuesday’s pre-market session. This is after a fall of more than 16% on Monday, following the company's announcement that CagriSema demonstrated 23% weight loss in people with obesity in the Redefine 4 trial,&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/why-is-nvo-stock-falling-pre-market-today/cZRtZlKR4UC">failing to meet</a> its primary endpoint.According to TheFly, analysts at JPMorgan downgraded Novo Nordisk to ‘Neutral’ from ‘Overweight’, calling the CagriSema results “disappointing.”The firm also further reduced its CagriSema forecasts by up to 63% through 2030, expecting a more challenging uptake for the product given its "inferiority" to Eli Lilly and Co.’s (LLY) Zepbound.Analysts at Kepler Cheuvreux downgraded NVO to ‘Hold’ from ‘Buy’ and stated that the company’s Redefine 4 study was a “major negative surprise.”Nordea analysts also downgraded Novo Nordisk to ‘Hold’ from ‘Buy’, with the firm citing a lack of near-term catalysts following Monday’s obesity study results.<a href="https://stocktwits.com/symbol/NVO">NVO stock</a> is down 23% year-to-date and 55% over the past 12 months.Also See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/is-microsoft-down-current-status/cZRtw5dR4yV">Is Microsoft Down? MSFT 365 Error Reports Spike On Downdetector, Company Says It Is Investigating The Issue</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

NVO Stock Continues To Decline Pre-Market After Monday’s Crash Amid CagriSema Setback – But Tuesday Brings Some Hope From China

Developed in partnership with United Laboratories International Holdings, Novo Nordisk said that UBT251 delivered up to 19.7% mean weight loss after 24 weeks in a phase 2 trial in China.

<ul class="summary-bullets"><li>The company stated that CagriSema failed to match tirzepatide in terms of effectiveness in its clinical trial.</li><li>People treated with CagriSema 2.4 mg/2.4 mg achieved a weight loss of 23.0% after 84 weeks compared to 25.5% with tirzepatide 15 mg, according to Novo.</li><li>When measuring the treatment effect regardless of adherence, people treated with CagriSema 2.4 mg/2.4 mg achieved a weight loss of 20.2% compared to 23.6% with tirzepatide at 84 weeks.</li></ul>Novo Nordisk AS (NVO) shares fell more than 14% in Monday’s pre-market trade after the company announced headline results from Redefine 4, an open-label phase 3 trial.Novo Nordisk stated that CagriSema demonstrated 23% weight loss in people with obesity, but it failed to meet its primary endpoint.Retail sentiment on Stocktwits around&nbsp;<a href="https://stocktwits.com/symbol/NVO">Novo Nordisk</a> trended in the ‘extremely bearish’ territory at the time of writing.<h2 class="st-heading-2">CagriSema Fails To Match Tirzepatide In Effectiveness</h2>Novo Nordisk stated that CagriSema failed to match tirzepatide in terms of effectiveness in its clinical trial.The company said that people treated with CagriSema 2.4 mg/2.4 mg achieved a weight loss of 23.0% after 84 weeks compared to 25.5% with tirzepatide 15 mg.When measuring the treatment effect regardless of adherence, people treated with CagriSema 2.4 mg/2.4 mg achieved a weight loss of 20.2% compared to 23.6% with tirzepatide at 84 weeks.“CagriSema has the potential to be the first GLP-1/amylin-combination product to reach the market for people living with obesity, documenting that cagrilintide adds to the existing benefits of semaglutide and offers clinically meaningful additive weight loss effects superior to what has been observed with GLP-1 biology alone,” said Novo Nordisk’s Chief Scientific Officer and Executive Vice President, Martin Holst Lange.<h2 class="st-heading-2">Who Is CagriSema Aimed At?</h2>CagriSema is a once-weekly subcutaneous treatment that is being investigated by Novo Nordisk for adults with overweight or obesity issues. It is also being considered as a treatment for adults with type 2 diabetes.The treatment is a fixed-dose combination of a long-acting amylin analogue, cagrilintide 2.4 mg, and semaglutide 2.4 mg.Novo Nordisk says CagriSema works by inducing weight loss by reducing hunger, increasing feelings of fullness, which helps people eat less and reduce their calorie intake.<a href="https://stocktwits.com/symbol/NVO">NVO stock</a> is down 7% year-to-date and 46% over the past 12 months.Also See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/trump-replicate-most-tariffs-after-supreme-court-ruling-goldman-sachs/cZRNfSqR4xV">Trump Administration Can Replicate Most Of The Tariffs, Says Goldman Sachs Following Supreme Court Rebuke: Report</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Why Is NVO Stock Falling Pre-Market Today?

The company stated that CagriSema demonstrated 23% weight loss in people with obesity, failing to meet its primary endpoint.

<ul class="summary-bullets"><li>It is unclear what the company intends to charge for the vials, the report said.</li><li>Unlike Novo, Eli Lilly and Company already sells its obesity drug Zepbound in both injector pen and vial formats. &nbsp;</li><li>Novo also has a pill version of its obesity drug called Wegovy pill launched in early January to regain its slipping market share in the obesity segment.</li></ul>Danish drugmaker Novo Nordisk (NVO) is reportedly looking to sell its injectable Wegovy in vials in a move that mirrors rival Eli Lilly and Company (LLY).Bloomberg<a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.bloomberg.com/news/articles/2026-02-11/novo-to-follow-lilly-and-sell-obesity-shot-wegovy-in-vials?srnd=homepage-americas"> reported </a>on Wednesday, citing Novo CEO Mike Doustdar, that the vials are slated to be introduced in the U.S. this year, followed by launches in other countries.It is unclear what the company intends to charge for the vials, the report said. &nbsp;<h2 class="st-heading-2">Wegovy Upgrade</h2>Presently, Novo sells Wegovy in injector pens. Unlike Novo, Eli Lilly sells its obesity drug Zepbound in both injector pen and vial formats. The vials were introduced about two years ago to increase supply, improve access, and offer a lower-cost option.Injector pens are the standard auto-injector devices, often preferred for ease of use as they do not require manual drawing of medication. Meanwhile, vials require the use of a separate needle and syringe to draw up the medication.Novo also has a pill version of its obesity drug called Wegovy pill launched in early January as it pushes to regain its slipping market share in the obesity segment.<h2 class="st-heading-2">Novo’s Disappointing Outlook</h2>Novo now <a href="https://stocktwits.com/news-articles/markets/equity/novo-nordisk-shares-tumble-on-q4-miss-weak-sales-forecast/cZbi6tLR4m0">expects</a> adjusted sales to fall between 5% and 13% in fiscal 2026, and operating profit could decline by up to 13%.The company flagged concerns for the year including fierce competition, lower realized prices, and expiry of patent on the active ingredient in its best-selling Wegovy and Ozempic drugs in a few markets outside the U.S. while issuing the guidance earlier this month.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment around NVO stock stayed within ‘bearish’ territory over the past 24 hours, while message volume fell from ‘extremely high’ to ‘high’ levels.<a href="https://stocktwits.com/symbol/NVO">NVO stock</a> is down 42% over the past 12 months.&nbsp;Read More: <a href="https://stocktwits.com/news-articles/markets/equity/entx-rallies-as-insiders-buy-company-shares/cZb6pAeR4Ah">ENTX Rallies As Insiders Buy Company Shares — Retail Hopes For ‘Exciting Days’ Ahead</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, a Novo Nordisk logo is displayed on a smartphone with stock market percentages in the background. (Photo Illustration by Omar Marques/SOPA Images/LightRocket via Getty Images)

Novo Nordisk Reportedly Eyes Launching Wegovy In Vials To Compete With Rival Eli Lilly 

Bloomberg reported on Wednesday, citing Novo CEO Mike Doustdar, that the vials are slated to be introduced in the U.S. this year.

AVDE
American Century ETF Trust - Avantis International Equity ETF

Feed

News

Sentiment

Fundamentals

Info

Poll

Latest AVDE News

AVDEAmerican Century ETF Trust - Avantis International Equity ETF